BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UM//UM*Events//EN
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/Detroit
TZURL:http://tzurl.org/zoneinfo/America/Detroit
X-LIC-LOCATION:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20070311T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20071104T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20250904T153242
DTSTART;TZID=America/Detroit:20260219T110000
DTEND;TZID=America/Detroit:20260219T120000
SUMMARY:Social / Informal Gathering:Weekly coffee chat hosted by INFORMS & HFES
DESCRIPTION:Come join us in the IOE Commons for some coffee and networking!
UID:138834-21896900@events.umich.edu
URL:https://events.umich.edu/event/138834
CLASS:PUBLIC
STATUS:CONFIRMED
CATEGORIES:Graduate,Graduate Students,Hfes,Human Factors And Ergonomics Society,Industrial And Operations Engineering,Michigan Engineering,Undergraduate,Undergraduate Students
LOCATION:Industrial and Operations Engineering Building - Community Suite, Room 1700
CONTACT:
END:VEVENT
BEGIN:VEVENT
DTSTAMP:20260202T162152
DTSTART;TZID=America/Detroit:20260219T113000
DTEND;TZID=America/Detroit:20260219T123000
SUMMARY:Presentation:Dr. Olga Morozova:  Extended-Release Buprenorphine (BUP-XR) for the Treatment of Opioid Dependence in the Context of the War in Ukraine
DESCRIPTION:Opioid agonist therapy (OAT) represents a critical intervention for reducing illicit opioid use and opioid-related mortality. Extended-release formulations of buprenorphine (BUP-XR) have demonstrated potential for enhancing treatment adherence and expanding access to care\; however\, findings from real-world implementation studies remain inconsistent. To date\, most evaluations of BUP-XR have been conducted in high-income settings.\n\nSince February 2022\, the full-scale war with Russia has placed individuals receiving OAT in Ukraine at substantial risk of treatment disruption due to displacement\, instability\, and interruptions in medication supply chains. In response to these challenges\, Ukrainian public health authorities secured a donation of BUP-XR (BuvidalⓇ) from the manufacturer\, Camurus AB (Sweden)\, and launched a pilot implementation program.\n\nDr. Morozova currently serves as a Multiple Principal Investigator (MPI) on a NIDA-funded study examining the impact of war-related trauma on HIV care engagement among individuals with a history of substance use disorders in Ukraine. She earned her Ph.D. in Epidemiology from the Yale School of Public Health and completed postdoctoral training in Biostatistics at Yale University. She also holds an M.S. in Mathematical Modeling in the Social Sciences and a B.S. in Applied Mathematics from the National University of Kyiv\, Ukraine.\n\nThis talk will report findings from a prospective\, multicenter\, open-label trial of monthly BUP-XR injections conducted across ten regions of Ukraine between February 2023 and August 2024. The results will be discussed within the broader context of wartime disruptions and adaptations in the national OAT program in Ukraine.\nThis event is co-sponsored by The Center for Russian\, East European and Eurasian Studies (CREES).
UID:144913-21896137@events.umich.edu
URL:https://events.umich.edu/event/144913
CLASS:PUBLIC
STATUS:CONFIRMED
CATEGORIES:Public Health
LOCATION:Public Health II - G020
CONTACT:
END:VEVENT
END:VCALENDAR